Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Bloomage BioTechnology Corporation Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 00963) RESIGNATION AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR CHANGE OF COMPOSITION OF THE AUDIT COMMITTEE, THE REMUNERATION COMMITTEE AND THE NOMINATION COMMITTEE

The Board announces the following changes with effect from 28 February 2014:
(i). Mr. Zhang has resigned as an independent non-executive Director, member of the Audit Committee and Nomination Committee and the chairman of the Remuneration Committee;
(ii). Mr. Qin has resigned as an independent non-executive Director, the chairman of the Audit Committee and a member of the Remuneration Committee;
(iii).Mr. Li has been appointed as an independent non-executive Director, the chairman of the Audit Committee and a member of the Remuneration Committee; and
(iv). Mr. Hai has been appointed as an independent non-executive Director, a member of the Audit Committee and Nomination Committee and the chairman of the Remuneration Committee.

- 1 -

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS

The board (the "Board") of directors (the "Directors") of Bloomage BioTechnology Corporation Limited (the "Company") announces that Mr. Zhang Fuping ("Mr. Zhang") has resigned as an independent non-executive Director, member of the audit committee (the "Audit Committee") and nomination committee (the "Nomination Committee") and chairman of the remuneration committee (the "Remuneration Committee") of the Company with effect from 28 February 2014 due to his other career development.
Mr. Zhang has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company.
The Board further announces that Mr. Qin Bin ("Mr. Qin") has resigned as an independent non-executive Director, chairman of the Audit Committee and member of the Remuneration Committee with effect from 28 February 2014, as he has been assigned to work in the United States.
Mr. Qin has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company.
The Board would like to take this opportunity to express its sincere gratitude to Mr. Zhang and Mr. Qin for their valuable contribution to the Company during their tenure of office.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS Mr. Li Junhong

The Board is pleased to announce that Mr. Li Junhong ("Mr. Li") has been appointed as an independent non-executive Director with effect from 28 February 2014.
Mr. Li Junhong, aged 47, graduated from Central University of Finance and
Economics (r:f!k:J!�jc�) with a Bachelor degree in Accounting in 1989. He studies
in the International Executive Master of Business Administration programme at the
China Center for Economic Research at Peking University (;Rjc�r:f���)fJZr:f

) from 2000 to 2002 and obtained a Master of Business Administration from

Fordham University in 2002. He is also a member of The Chinese Institute of
Certified Public Accountants. From January 2008 to December 2008, Mr. Li had been an executive director of Hong Kong Life Sciences and Technologies Group Ltd. (W

1t�ifu4�1ìill�lll:1�%PJ) (formerly known as Zmay Holdings Limited and New

Chinese Medicine Holdings Limited) (stock code: 8085), a company listed on the
- 2 -
Growth Enterprise Market of The Stock Exchange of Hong Kong Limited. He has over 20 years of experience in auditing, accounting, merger and acquisition consultancy and management consultancy with local accountants firms and private companies. He was a partner in Beijing Tianhua CPAs ( ;R7($i'"tf1��)). Mr. Li is now the executive vice president and the financial controller of Zhongrong Financial Investment Management Company Limited (r:frti�/llfi(��lf!:1�%PJ).
Save as disclosed above, Mr. Li does not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years or any other position with the Company and other members of the Group or other major appointments and professional qualifications.
Mr. Li does not have any relationship with other Directors, senior management, substantial or controlling shareholders of the Company and he has no interests in the shares of the Company which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) (the "SFO").
Mr. Li has entered into a director 's service agreement with the Company for a term of one year commencing on 28 February 2014 subject to rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company. The service agreement can be terminated by either party by giving the other party one month written notice in advance. The director 's remuneration of Mr. Li is HK$150,000 per annum which is determined with reference to his duties and responsibilities within the Company.
Save as disclosed above, there are no other matters relating to the appointment that need to be brought to the attention of the shareholders of the Company and there is no other information that should be disclosed pursuant to paragraphs 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules").

Mr. Hai Wen

The Board is also pleased to announce that Mr. Hai Wen ("Mr. Hai") has been appointed as an independent non-executive Director with effect from 28 February
2014.
- 3 -
Mr. Hai Wen, aged 61, graduated from Peking University with a Bachelor degree in Economics in 1982. He obtained a doctorate degree in Economics from the University of California, Davis in 1991. He is a professor in Economics and doctoral supervisor of Peking University and currently serves as the deputy director of the University Council of Peking University ( ;Rjc�;S��Jli'") and the dean of the HSBC Business School of Peking University ( ;Rjc�ìll'l!i>�m). He had been a permanent deputy director of The China Center for Economic Research at Peking University ( ;Rjc�r:f���)fJZr:f�), vice principal of Peking University and the dean of the Shenzhen Graduate School of Peking University ( ;Rjc�ii�)fJZ�

m). Mr. Hai had compiled and translated more than ten books on Economics and has won several awards in the fields of Economics and education.

Save as disclosed above, Mr. Hai does not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years or any other position with the Company and other members of the Group or other major appointments and professional qualifications.
Mr. Hai does not have any relationship with other Directors, senior management, substantial or controlling shareholders of the Company and he has no interests in the shares of the Company which are required to be disclosed pursuant to Part XV of the SFO.
Mr. Hai has entered into a director 's service agreement with the Company for a term of one year commencing on 28 February 2014 subject to rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company. The service agreement can be terminated by either party by giving the other party one month written notice in advance. The director 's remuneration of Mr. Hai is HK$200,000 per annum which is determined with reference to his duties and responsibilities within the Company.
Save as disclosed above, there are no other matters relating to the appointment that need to be brought to the attention of the shareholders of the Company and there is no other information that should be disclosed pursuant to paragraphs 13.51(2)(h) to (v) of the Listing Rules.
The Board would like to express its warm welcome to Mr. Li and Mr. Hai on their appointment as an independent non-executive Director.
- 4 -

CHANGE OF COMPOSITION OF THE AUDIT COMMITTEE, THE REMUNERATION COMMITTEE AND THE NOMINATION COMMITTEE

The Board also announces that (i) Mr. Li has also been appointed as the chairman of the Audit Committee and a member of the Remuneration Committee; and (ii) Mr. Hai has been appointed as a member of the Audit Committee and the Nomination Committee and the chairman of the Remuneration Committee. The above appointments are effective from 28 February 2014.
Hong Kong, 28 February 2014
By order of the Board

Bloomage BioTechnology Corporation Limited ZHAO YAN

Chairman

As at the date of this announcement, the executive Directors are Ms. Zhao Yan, Mr. Jin Xuekun, Ms. Liu Aihua and Ms. Wang Aihua; the non-executive Director is Mr. Guo Jiajun; the independent non-executive Directors are Ms. Zhan Lili, Mr. Li Junhong and Mr. Hai Wen.

- 5 -

distributed by